

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
27 March 2025 (27.03.2025)



(10) International Publication Number
WO 2025/064502 A1

(51) International Patent Classification:

C07B 59/00 (2006.01) A61P 25/24 (2006.01)

C07D 217/04 (2006.01)

NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(21) International Application Number:

PCT/US2024/047209

(22) International Filing Date:

18 September 2024 (18.09.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/583,710 19 September 2023 (19.09.2023) US

63/681,004 08 August 2024 (08.08.2024) US

(71) Applicant: **XENON PHARMACEUTICALS INC.**
[CA/CA]; 200-3650 Gilmore Way, Burnaby, BC V5G 4W8 (CA).

(72) Inventors: **CLARK, Michael, Philip**; c/o Xenon Pharmaceuticals Inc., 3650 Gilmore Way, Burnaby, BC V5G 4W8 (CA). **ZENOVA, Alla, Yurevna**; c/o Xenon Pharmaceuticals Inc., 3650 Gilmore Way, Burnaby, BC V5G 4W8 (CA). **DEHNHARDT, Christoph, Martin**; c/o Xenon Pharmaceuticals Inc., 3650 Gilmore Way, Burnaby, BC V5G 4W8 (CA).

(74) Agent: **SAMBLANET, Danielle, C.** et al.; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210-2206 (US).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: DEUTERIUM AND ARYL AMINE COMPOUNDS AND USES THEREOF



(57) Abstract: Provided herein are compounds, including compounds of any of the formulae described herein (e.g., Formula (I)), and pharmaceutically acceptable salts, stereoisomers, tautomers, solvates, hydrates, and prodrugs thereof. Compounds provided herein can act as potentiators of voltage-gates potassium channels (e.g., Kv7 potassium channels such as Kv7.2/Kv7.3) and are therefore useful in the treatment and/or prevention of diseases, disorders, and conditions (e.g., diseases, disorders, and conditions associated with Kv7 potassium channel dysfunction).

WO 2025/064502 A1